A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 by Cole, M. P. et al.
270
A NEW ANTI-OESTROGENIC AGENT IN LATE BREAST CANCER
AN EARLY CLINICAL APPRAISAL OF IC146474
M. P. COLE, C. T. A. JONES AND I. D. H. TODD
From the Christie Hospital and Holt Radium Institute, Manchester M20 9BX
Received for publication April 7, 1971
SUMMARY.-An introductory clinical trial of the anti-oestrogenic agent
IC146474 in late or recurrent carcinoma of the breast is described.
Forty-six patients havebeentreated, ofwhom 10have shownagood response.
This is of the same order as that seen with oestrogens and androgens.
The particular advantage of this drug is the low incidence of troublesome
side effects.
ALTHOUGH the value of hormones in the palliative treatment of recurrent
breast cancer is well established, clinical experience shows that only a proportion
of cases respond. Laboratory tests designed to select those patients likely to
benefit have produced inconclusive results and treatment has therefore been
conducted on a trial and error basis.
The current practice in this hospital is to offer irradiation ofthe ovaries at the
time of initial treatment of the breast cancer to all pre-menopausal women and
to those within 3 years of the menopause. The advantage of this scheme was
demonstrated by clinical trial (Paterson and Russell, 1959; Cole, 1967).
Patients with recurrence of carcinoma of the breast or metastases which are
judged not suitable for radiotherapy receive hormone therapy. The younger
patient within 5 years of the menopause receives androgens with or without
additional cytotoxic drugs whilst the older patient 5 years or more past the meno-
pause receives oestrogens. The group which shows the poorest response rate
to hormone therapy is composed of those patients who develop their carcinoma
at about the time ofthe menopause.
ICI46474
ICI46474 is the trans-isomer of l(p-beta-dimethylaminoethoxy-phenyl)-l,
2-diphenylbut-l-ene. In several, but not all mammalian species, it is a potent
anti-oestrogen. Thus in low doses it opposes the action of exogenous oestrogens
in cornifying the vaginal epithelium and increasing uterine weight in immature
rats (Harper and Walpole, 1966). Similarly, when given to rats on the third or
fourth day of pregnancy, it will prevent implantation of the fertilized ova by
counteracting the augmented endogenous oestrogen release required to initiate
implantation in this species (Harper andWalpole, 1967a, 1967b). In a single dose,
given at the appropriate time to cycling female rats, it will delay ovulation by
interfering with the oestrogen-dependent ovulatory release of luteinizing hormone
(Labhsetwar, 1970). All these effects are almost certainly due to competitiveANTI-OESTROGENIC AGENT IN BREAST CANCER
interference with oestradiol uptake byspecific receptors at various sites (Skidmore,
unpublished data). However, the possibility that ICI46474 will also inhibit the
production of oestrogen cannot be excluded on present evidence. Furthermore,
very high doses of the drug have oestrogenic effects in rats. Since low doses of
IC146474 also evoke anti-oestrogenic responses in monkeys (Walpole, unpublished),
it was thoughtprobable that man wouldrespondsimilarly and a number ofpossible
clinical applications weresuggested. These include the treatment ofsomepatients
with infertility due to failure ofovulation, as with clomiphene an agent ofsimilar
chemical structure (Walpole, 1968)-and apossible contraceptive effectifoestrogen
is essential for implantation of the fertilized ovum in humans. A preliminary
communication on the effect of this drug in causing ovulation in secondary
amenorrhoea has been published by Klopper and Hall (1971). An action on
hormone dependent breast cancer was also considered and it was decided that a
trial ofthe compound in such cases would be a suitable introduction to its clinical
study.
PATIENTS AND METHODS
All patients treated with IC146474 had breast cancer, proved by biopsy. In
every case, the extensive nature of the disease precluded a curative approach by
surgery or radiotherapy. The majority ofpatients had already been treated with
hormones or alkylating agents and all were post-menopausal. The drug was
supplied in 10 mg. tablets, the dose being 1 or 2 tablets daily.
A response to the agent was accepted when there was a substantial reduction
in size ofsoft tissue masses and/or radiological evidence ofregression ofpulmonary
or bone metastases, together with subjective improvement, this being sustained
for more than 3 months. Care was taken to ensure that no response could have
been the result of treatment with, or withdrawal of, another hormone, or to any
other form ofcoincidental treatment, particularly irradiation or antibiotic therapy.
Those failing to respond to ICI46474 showed no subjective or objective improve-
ment of any duration, but a large intermediate group was also noted. These
latter patients showed subjective improvement without objective clinical or
radiographical regression, or ifsuch regression did occur, its duration was less than
3 months, or could have been attributedto another coincidental form oftherapy.
The following measurements were made routinely in all patients:
haemoglobin
total and differential white cell count
platelet count
erythrocyte sedimentation rate (ESR)
serum calcium
serum inorganic phosphate
serum alkaline phosphatase
blood urea
serum alanine aminotransferase (SGPT)
In some patients, the following additional investigations were made:
determination of serum cholesterol and desmosterol levels, examination of
vaginal smears and estimation ofplasma oestrogen levels.
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RESULTS
Forty-six patients have received ICI46474 for longer than 3 months. Their
age distribution is shown in Table I. Ten patients (22%) have shown a clear
TABLE I.-Patients Treated with IC146474
Age (years) 30-39 40-49 50-59 60-69 70-79 80-89
Total number treated . 1 . 10 13 17 . 4 1
Number responding . 0 . 4 1 . 3 2 . 0
response as defined above. Nineteen patients have failed to respond, whilst
17 patients have demonstrated an incomplete or indeterminate response. In 7
oftheresponding cases, malignant infiltration ofthe skin ofthe chest wallregressed
or healing of a malignant ulcer occurred. Two patients showed radiological
resolution of pulmonary metastases whilst in 1 instance, lytic bone metastases
re-ossified.
A total of 19 side effects were reported and these were as follows:
hot flushes 7
gastro-intestinal intolerance 6
tumour pain 2
pruritus vulvae 1
ankle oedema 1
vaginal bleeding 1
lassitude 1
Manyofthese reactions were mild andwere onlyadmittedto on direct question-
ing. On only 2 occasions (4 %) has treatment been prematurely discontinued
because of toxic reactions-I patient suffered intolerable hot flushes, and the
other, nausea and vomiting. This latter patient experienced similar difficulty
in taking other tablets of various types. Neither patient who suffered tumour
pain benefited from IC146474.
Certain features noted during the routine blood tests deserve comment. On
4 occasions, platelet counts fell to less than 80,000/mm.3 in each instance returning
spontaneously to normal without discontinuing ICI46474. Three patients,
enjoying a clinical response, showed a transient rise in serum alanine amino-
transferase (SGPT) and it was suggested, in the absence ofany additional evidence
of hepatotoxicity, that this was the result of increased neoplastic cell destruction
by the drug. In all responders except one, the erythrocyte sedimentation rate,
ifinitially raised, fell to normal during treatment as the patient's general condition
improved. A raised alkaline phosphatase level returned to the normal range in
2 patients. Estimation of cholesterol and desmosterol revealed normal ratios on
25 occasions.
There has been no evidence ofhepatotoxicity and no hypercalcaemia. Vaginal
smears showed no characteristic pattern and in these post-menopausal women,
plasma oestrogen levels were too low initially to permit further useful study.
EVALUATION
When evaluating the results with ICI46474, an unpublished trial of diethyl-
stilboestrol against the oral androgen methylandrostenediol, conducted at this
hospital, was used for purposes of comparison.
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All patients entering this trial had recurrent breast cancer which had reached
a stage where further surgery or radiotherapy was unlikely to be curative. Every
patient was more than 5 years post-menopausal and none had previously received
hormones. The patients were randomly assigned to 2 groups; 1 group received
diethylstilboestrol in a dose of 5 mg. orally 3 times daily, whilst the second group
was treated with methylandrostenediol in a dose of 50 mg. 4 times daily sub-
lingually. Responses were assessed according to the criteria described above for
ICI46474.
Sixty-four patients received diethylstilboestrol, of whom 16 (25 %) responded.
Sixtypatientsreceivedmethylandrostenedioland 10(16 %)responded. Regression
of soft tissue disease accounted for the majority of responses in both groups.
Thirty-six patients receiving diethylstilboestrol experienced side effects and these
were ofsufficient severity to terminate treatment on 12 occasions (18 %). Gastro-
intestinal intolerance, fluid retention and vaginal bleeding were the commonest
toxic reactions encountered. Intolerance to methylandrostenediol was observed
on 17 occasions; treatment however was discontinued for this reason in only 5
instances (8 %). Fluid retention, vomiting and virilization were the most trouble-
some side effects inthisgroup.
Despite the differences in the method of selection of patients who received
ICI46474 as opposed to those who entered the oestrogen-androgen trial, the
criteria adopted for assessment of responses were identical in both series. A
limited comparison of the results obtained with the three agents has therefore
been made.
The response rates to the 3 drugs are shown in Table II and the incidence of
side effects in Table III.
Where diethylstilboestrol or methylandrostenediol was administered before
ICI46474, the responses are summarized in Tables IV and V. No striking pattern
reveals itself. In particular, there is no obvious correlation in this limitednumber
ofcasesbetween androgen responseandantioestrogen responseinthe sametumour.
TABLE II
Response
Hormone rate (%)
Diethylstilboestrol . 25 (16/64)
Methylandrostenediol . 16 (10/60)
ICI46474 . . . 22 (10/46)
P > 0 05
TABLE III.-Side Effects ofHormones
Diethylstilboestrol Methylandrostenediol ICI46474
Patients receiving hormone . . 64 . 60 . 46
Number of patients showing side effects. 36 (64%) . 17 (28%) . 17 (37%)
Drug discontinued on account of
side effects . . . . . 12 (18%) * 6 (8%) . 2 (4%)
TABLE IV.-Previous Hormone Treatment in Patients Responding to IC146474
Hormone Response No response
Diethylstilboestrol . 3 . 2
Methylandrostenediol . 1 . 1
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TABLE V.-Previous Hormone Treatment in Patients who Failed to
Respond to ICI46474
Hormone Response No response
Diethylstilboestrol . 3 . 9
Methylandrostenediol . 5 . 7
Eleven of the 46 patients were treated with a dose of 10 mg. daily. Of the
11 receiving the lower dose, 4 were classed as responders.
DISCUSSION
The evidence that ICI46474 is an oestrogen antagonist in rats and in monkeys
is convincing and the likelihood that a similar effect would be seen also in man led
to this trial in recurrent breast cancer. The chemically related agent clomiphene
has already been used in similar cases with some evidence ofresponse, although the
mechanism of action in this situation was not conclusively proved (Herbst et al.,
1964).
The remission rate of 22 % induced by ICI46474 in this series of patients is
similar to that usually obtained with hormones. It has not been possible to
confirm by laboratory investigation that ICI46474 acts directly on breast tumours
by oestrogen antagonism, owing to the low levels of circulating oestrogens found
in these patients, but the occurrence, or exacerbation, of hot flushes in some
treated patients suggests that this is the likely explanation. This particular side
effect was not observed when using diethylstilboestrol or methylandrostanediol.
Although the response rates in the oestrogen-androgen trial compare closely
with that for IC146474, the incidence of side effects of sufficient severity to ter-
minate treatment with the latter is lower, particularly when compared with
diethylstilboestrol. Gastro-intestinal intolerance and fluid retention are less
marked following the anti-oestrogen than diethylstilboestrol, whilst the virilizing
effect of androgens has not been seen with ICI46474. The occasional fall in the
platelet count is difficult to explain, although 3 of the 4 patients had received
alkylating agents before ICI46474. The lower toxicity of the anti-oestrogen
seems to constitute its main advantage over other hormones.
Four of the 10 responses to ICI46474 occurred in the fifth decade, within 3
years of the menopause, a group which in the past has usually been particularly
insensitive to hormone therapy.
There is no convincing correlation between androgen responsiveness and anti-
oestrogen responsiveness of the same tumour. Cases relapsing after a beneficial
response to a standard hormone may be expected in some cases to respond later
to IC146474 in view ofits different mode ofaction.
We are grateful to Dr. R. T. Rouse and Dr. A. L. Walpole for their advice and
to Imperial Chemical Industries Limited for supplying ICI46474.
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